Le 15 mai 2019

Article publié : Efficacité à long terme de l’ustekinumab dans la maladie de Behçet.

Le 15 mai 2019

Article publié : Efficacité à long terme de l’ustekinumab dans la maladie de Behçet.

Notre équipe vient de publié un article concernant l’efficacité de l’ustekinumab dans la maladie de Behçet.

 

Résumé :

OBJECTIVE:

Oral ulcers (OU), the hallmark lesion of Behçet’s disease (BD), can be disabling and resistant to conventional treatment. There remains a need for safe and effective treatment. We report here the long term safety and efficacy of ustekinumab therapy for BD related OU resistant to colchicine.

Patients and method

Multicenter prospective open label study including 30 patients fulfilling criteria of the International Study Group for BD and with active OU resistant to colchicine. Patients were treated with ustekinumab 90 mg subcutaneously at inclusion, at week 4, and every 12 weeks. The primary efficacy endpoint was the proportion of patients with complete response (CR) at week 12, defined as patients who had no oral ulcer.

Results

The median number of OU per patient was significantly lower at week 12 of ustekinumab therapy compared to baseline [0 [0-1] vs. 2 [2-3], p<0.0001]. Complete response was achieved in 60.0% and 88.9% at week 12 and 24, respectively. The median Behçet’s syndrome activity score (in which higher scores indicating a more active disease) was significantly lower at week 12 and 24 compared to baseline [70 [50-70] vs. 17.5 [10-42.5] and 10 [8-11], respectively, p<0.0001]. After a median follow-up of 12 [6-16] months, 26 (86.6%) patients were still receiving ustekinumab treatment. Reasons for ustekinumab withdrawal included BD flare (n=3) and side effect (n=1). There were 7 (23.3%) adverse events including headaches (n=4) and asthenia (n=2), with no serious side effect.

Conclusion

Ustekinumab seems to be effective in BD related oral ulcers resistant to colchicine. This article is protected by copyright. All rights reserved.

 

 

Pour lire l’article : cliquer ici